Results 21 to 30 of about 30,272 (291)
The clinical landscape of CAR NK cells. [PDF]
Exp Hematol OncolAbstract Chimeric antigen receptor (CAR) NK cell therapy has emerged as a promising alternative to CAR T cell therapy, offering significant advantages in terms of safety and versatility. Here we explore the current clinical landscape of CAR NK cells, and their application in hematologic malignancies and solid cancers, as well as their ...
Jørgensen LV +3 more
europepmc +4 more sources
CAR-NK Cells in the Treatment of Solid Tumors [PDF]
International Journal of Molecular Sciences, 2021 CAR-T (chimeric antigen receptor T) cells have emerged as a milestone in the treatment of patients with refractory B-cell neoplasms. However, despite having unprecedented efficacy against hematological malignancies, the treatment is far from flawless.
Ewa Wrona +2 more
openaire +2 more sources
CAR‐NK cell in cancer immunotherapy; A promising frontier [PDF]
Cancer Science, 2021 AbstractChimeric antigen receptors (CARs) have a unique facet of synthetic biology and offer a paradigm shift in personalized medicine as they can use and redirect the patient's immune cells to attack cancer cells. CAR‐natural killer (NK) cells combine the targeted specificity of antigens with the subsequent intracellular signaling ability of the ...
Faroogh Marofi +12 more
openaire +2 more sources
IPSC-derived CAR-NK cells for cancer immunotherapy
Biomedicine & Pharmacotherapy, 2023 Adoptive cell therapies (ACT) based on chimeric antigen receptor (CAR)-modified immune cells have made great progress with six CAR-T cell products approved by the U.S. FDA for hematological malignancies. Compared with CAR-T cells, CAR-NK cells have attracted increasing attention owing to their multiple killing mechanisms, higher safety profile, and ...
Xiaotong, Lin +5 more
openaire +2 more sources
CAR NK Cells: The Future Is Now
Annual Review of Cancer Biology, 2023 Chimeric antigen receptor (CAR) T cell therapy has been a great success in CD19+ hematological diseases. Natural killer (NK) CAR cells offer an alternative to CAR T cells with an intrinsic potential for universal off-the-shelf cell therapeutics.
Martin J. Raftery +2 more
openaire +1 more source
Review of precision cancer medicine: Evolution of the treatment paradigm. [PDF]
, 2020 In recent years, biotechnological breakthroughs have led to identification of complex and unique biologic features associated with carcinogenesis. Tumor and cell-free DNA profiling, immune markers, and proteomic and RNA analyses are used to identify ...
Fountzilas, Elena +3 more
core +1 more source
Engineering NK Cells for CAR Therapy—Recent Advances in Gene Transfer Methodology [PDF]
, 2021 The development of chimeric antigen receptor (CAR) T cell therapy has introduced a new and effective strategy to guide and promote the immune response against tumors in the clinic. More recently, in an attempt to enhance its utility, this method has been
Pecher, Gabriele +2 more
core +1 more source
Current Progress of CAR-NK Therapy in Cancer Treatment
Cancers, 2022 CD8+ T cells and natural killer (NK) cells eliminate target cells through the release of lytic granules and Fas ligand (FasL)-induced target cell apoptosis. The introduction of chimeric antigen receptor (CAR) makes these two types of cells selective and effective in killing cancer cells.
Zhaojun Pang +4 more
openaire +2 more sources
Overcoming tumor resistance mechanisms in CAR-NK cell therapy
Frontiers in Immunology, 2022 Despite the impressive results of autologous CAR-T cell therapy in refractory B lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost-effective approach with no signs of severe toxicities as described for CAR-T cells.
Antonio Valeri +16 more
openaire +4 more sources
Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma [PDF]
, 2017 Background aims Natural killer (NK) cells can rapidly respond to transformed and stressed cells and represent an important effector cell type for adoptive immunotherapy.
Bader, Peter +10 more
core +2 more sources